[HTML][HTML] Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a …
L Yuan, GD Jia, XF Lv, SY Xie, SS Guo, DF Lin… - Nature …, 2023 - nature.com
Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment
of certain solid tumors, but effective regimens remain elusive for refractory …
of certain solid tumors, but effective regimens remain elusive for refractory …
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single …
L Yuan, GD Jia, XF Lv, SY Xie, SS Guo… - Nature …, 2023 - econpapers.repec.org
Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment
of certain solid tumors, but effective regimens remain elusive for refractory …
of certain solid tumors, but effective regimens remain elusive for refractory …
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single …
L Yuan, GD Jia, XF Lv, SY Xie, SS Guo… - Nature …, 2023 - ui.adsabs.harvard.edu
Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment
of certain solid tumors, but effective regimens remain elusive for refractory …
of certain solid tumors, but effective regimens remain elusive for refractory …
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single …
L Yuan, GD Jia, XF Lv, SY Xie, SS Guo… - Nature …, 2023 - search.ebscohost.com
Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment
of certain solid tumors, but effective regimens remain elusive for refractory …
of certain solid tumors, but effective regimens remain elusive for refractory …
[HTML][HTML] Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a …
L Yuan, GD Jia, XF Lv, SY Xie, SS Guo… - Nature …, 2023 - ncbi.nlm.nih.gov
Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment
of certain solid tumors, but effective regimens remain elusive for refractory …
of certain solid tumors, but effective regimens remain elusive for refractory …
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single …
L Yuan, GD Jia, XF Lv, SY Xie, SS Guo… - Nature …, 2023 - europepmc.org
Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment
of certain solid tumors, but effective regimens remain elusive for refractory …
of certain solid tumors, but effective regimens remain elusive for refractory …
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single …
L Yuan, GD Jia, XF Lv, SY Xie, SS Guo… - Nature …, 2023 - pubmed.ncbi.nlm.nih.gov
Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment
of certain solid tumors, but effective regimens remain elusive for refractory …
of certain solid tumors, but effective regimens remain elusive for refractory …
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single …
L Yuan, GD Jia, XF Lv, SY Xie, SS Guo… - Nature …, 2023 - ideas.repec.org
Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment
of certain solid tumors, but effective regimens remain elusive for refractory …
of certain solid tumors, but effective regimens remain elusive for refractory …